The diagnosis of endometriosis and fertility disorders is difficult; therefore, it is necessary to look for reliable biomarkers. Analysis of the molecular status of fibronectin as a key player in repair and wound healing processes, as well as in coagulation and fibrinolysis pathways, is justified. ELISA and SDS-agarose immunoblotting were applied to determine the fibronectin concentration and presence and occurrence of soluble FN-fibrin complexes in the blood plasma of women with endometriosis (n = 38), fertility disorders (n = 28) and the healthy group (n = 25). The concentration of fibronectin in the blood plasma of women with endometriosis (292.61 ± 96.17 mg/L) and fertility disorders (287.53 ± 122.68 mg/L) was significantly higher than in the normal group (226.55 ± 91.98 mg/L). The presence of FN-fibrin complexes of 750, 1000, 1300, 1600 and 1900 kDa in the plasma of women with endometriosis and fertility disorders was shown. The presence of FN-fibrin complexes with a molecular mass of more than 1300 kDa in women with endometriosis and infertility and the complete absence of these complexes in healthy women may indicate an increased and chronic activation of coagulation mechanisms in these patients. The presence of complexes of high molecular mass may be one of the biomarkers of fertility disorders in women.
12 January 2023 in American Journal of Reproductive Immunology
Problem: Interleukin 35 (IL‐35) is involved in the pathogenesis of endometriosis by suppressing immunoreaction and promoting endometrial cell proliferation. It may also be an essential cytokine in forming the immunosuppressive functions of regulatory B lymphocytes (Bregs). The involvement of Bregs in the pathogenesis of endometriosis has not been previously investigated. In this study, we determined the frequencies of different Breg subpopulations, namely, B10, immature B‐cells, and plasmablasts, and their abilities to produce IL‐35 in women with endometriosis compared to healthy women.Methods: The frequencies of different subpopulations of Bregs producing IL‐35 were measured in the peripheral blood of women with endometriosis (total pool), women with deep infiltration endometriosis (DIE), women with ovarian endometriosis, and healthy women as a control by flow cytometry.Results: We observed a decrease in the percentage of B10 cells and plasmablasts in women with endometriosis and an increase in the percentage of these Breg populations producing IL‐35 in the same experimental group. Interestingly, we also revealed that women with DIE had increased percentages of B10 cells and plasmablasts producing IL‐35.Conclusion: Taken together, our findings are the first to reveal the frequencies of different subpopulations of Bregs producing IL‐35 in women with endometriosis. The results suggest that IL‐35 expression in B lymphocytes could be used as a peripheral marker of endometriosis; however, further studies are needed.
Immunological dysregulation may be involved in pregnancy loss. Regulatory T (Treg) and B (Breg) cells, together with interleukin-35 (IL-35), contribute to maternal-fetal tolerance. This study investigated peripheral regulatory cell populations in healthy pregnancy and recurrent spontaneous pregnancy loss (RPL), focusing on the potential relationships between regulatory B and T cells within a coordinated immunoregulatory network associated with immune tolerance during pregnancy. Peripheral blood samples were collected from healthy pregnant women and women following spontaneous miscarriage. Frequencies of Breg subsets, including B10 cells, immature B cells, and plasmablasts, as well as the proportions of cells expressing IL-35, IL-10, PD-L1, and PD-L2, were analyzed. Tregs and the regulatory T-cell subsets iTr35, Tr1, and Th3 were also examined for the expression of IL-35, IL-10, TGF-β, and PD-1. In addition, correlations between Treg and Breg populations were assessed. Miscarriage was associated with significantly reduced frequencies of IL-35+ immature B cells, IL-35+ B10-like cells, IL-35+ plasmablasts, IL-35+ Tregs, and iTr35 cells. A negative correlation was observed between PD-L1-expressing B10-like cells and the frequencies of Treg and Th3 cells. Notably, this study is the first to demonstrate a positive correlation between IL-35-producing Bregs and iTr35 cells in healthy pregnancy. These findings suggest that the observed relationships between peripheral regulatory B- and T-cell populations and IL-35-associated regulatory subsets may be relevant to immune regulation during pregnancy. The iTr35/IL-35+ Breg ratios showed potential discriminatory value between healthy pregnancy and pregnancy loss groups and may warrant further investigation as candidate markers in prospective studies.
Maternal immune tolerance and controlled inflammatory responses are essential for fetal development and successful pregnancy. Regulatory T cells (Tregs) and B cells with regulatory properties (Bregs) maintain this balance by limiting excessive immune activation through the secretion of anti-inflammatory and tolerogenic cytokines, such as IL-10, TGF-β, and IL-35. Moreover, alterations in the costimulatory potential of antigen-presenting cells (APCs), including B cells, modulate the activation and differentiation of T cells. Toll-like receptors (TLRs), particularly TLR9, influence B-cell antigen presentation and cytokine production, thereby affecting the balance between pro-inflammatory and tolerogenic responses at the maternal–fetal interface. TLR9 overexpression has been observed in several pregnancy-related disorders in both humans and murine models. In this study, we examine whether blocking TLR9 shortly after mating could improve pregnancy outcomes and modulate the regulatory and antigen-presenting functions of B cells, as well as their interactions with T cells. Using an abortion-prone murine model (CBA/J × DBA/2J), we show that intraperitoneal administration of a TLR9 antagonist (ODN 2088) shortly after mating increases embryo resorption in CBA/J females compared to controls without affecting implantation. Flow cytometry analysis further reveals that mice receiving the TLR9 antagonist are characterized by downregulation of CD80 and upregulation of CD86 on B cells, accompanied by reduced expression of CD40L and CD28 on T cells, as well as a lower percentage of Tregs and activated T cells. In conclusion, blocking TLR9 signaling shortly after mating does not improve pregnancy outcomes; conversely, it exacerbates pregnancy loss in the CBA/J × DBA/2J abortion-prone model, while altering the costimulatory phenotype of B and T cells and impairing Treg development during pregnancy.